de Carvalho Filho Eleazar
Known title: DirectorCIK: 0001494252
Associated companies
Transaction History
| FTI | ▼ Sell | Open Market | 6,350 | $415K | 2/25/2026 | View on chart |
| FTI | ▲ Buy | Grant | 3,259 | $0 | 2/16/2026 | View on chart |
| FTI | ▼ Sell | Open Market | 9,381 | $279K | 3/24/2025 | View on chart |
| FTI | ▲ Buy | Grant | 6,350 | $0 | 2/24/2025 | View on chart |
| FTI | ▼ Sell | Open Market | 12,491 | $265K | 2/23/2024 | View on chart |
| FTI | ▲ Buy | Grant | 9,381 | $0 | 2/20/2024 | View on chart |
| FTI | ▼ Sell | Open Market | 22,208 | $335K | 3/9/2023 | View on chart |
| FTI | ▲ Buy | Grant | 12,491 | $0 | 2/21/2023 | View on chart |
| FTI | ▲ Buy | Grant | 22,208 | $0 | 3/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Analyst Coverage Updates for TechnipFMC (FTI)
Barclays keeps an overweight stance on TechnipFMC but lowered its price target to $86. UBS has initiated coverage with a buy rating and a target of $89. These updates reflect a mixed but generally positive view from analysts, amid a sector backdrop highlighted by Halliburton's Q3 earnings preview.
Analyst Coverage Updates for TechnipFMC (FTI). Barclays keeps an overweight stance on TechnipFMC but lowered its price target to $86. UBS has initiated coverage with a buy rating and a target of $89. These updates reflect a mixed but generally positive view from analysts, amid a sector backdrop highlighted by Halliburton's Q3 earnings preview.